![Tretten® (coagulation factor XIII A-subunit [recombinant]) logo](/content/dam/novonordisk/novomedlink/logos/bleeding-disorders/tretten.svg)
For routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency. Not for congenital Factor XII B-subunit deficiency.
Purely because they are one in a million1
Tretten® is the only recombinant therapy approved for congenital FXIII A-subunit deficiency, a very rare autosomal recessive bleeding disorder that occurs in ≈1 in every 3 to 5 million people.2-5
Manny has
congenital
FXIII
deficiency
Efficacy and safety of Tretten®
Helping your patients with congenital FXIII A-subunit deficiency
Learn more about Tretten® dosing and storage
The Medical and Scientific Advisory Council (MASAC) recommends the use of Tretten® for patients with congenital FXIII A-subunit deficiency.6
Financial programs and support for patients
Novo Nordisk provides assistance through NovoCare®, a network to help your patients access co-pay savings, product support, and more.
NovoCare® is designed for your patients
Patients can access:
- Product support programs that help with treatment costs
- Representatives who speak Spanish to better serve them
You can help your patients by calling 1-844-668-6732 or have them contact NovoCare® at NovoCare.com.
NovoCare® can help with:
QuickCheck™ benefits verification
Verify your patients’ benefits and receive confirmation of coverage. If no coverage is available, names of alternative therapies may be supplied.
Patient Assistance Program (PAP)
See if your patients are eligible to receive their treatment free of charge. No registration or monthly fees required.
Patient Trial Program
Find out if your patients qualify to receive a limited supply of Novo Nordisk’s product for free.
Patient
enrollment form
Download and complete the patient enrollment form to attest your patient’s need for treatment.
Additional resources for patients
Tretten® trial prescription program
![Tretten® (Coagulation Factor XIII A-Subunit [Recombinant]) box with contents displayed](/rare-bleeding-disorders/products/treatments/tretten/_jcr_content/root/slab_2001454005_copy/content/container/image_copy.img.png/1663187125377/tretten-prescription.png)
Considering Tretten® for your patients with congenital FXIII A-subunit deficiency?
To learn more about our trial prescription program, please call 1-844-668-6732 to speak with a NovoCare® Specialist.
Looking for other Tretten® resources?
Important Safety Information for Tretten®
Tretten® is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.
Tretten® may cause allergic reactions. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.
Thromboembolic complications may occur. Monitor patients with conditions that predispose to thrombosis for signs and symptoms of thrombosis after administration of Tretten®.
Inhibitory antibodies may occur with Tretten®. Patients with inhibitory antibodies may manifest as an inadequate response to treatment. If expected plasma FXIII activity levels are not attained, or if breakthrough bleeding occurs while receiving prophylaxis, perform an assay that measures FXIII inhibitory antibody concentrations.
The most common adverse reactions reported in clinical trials (≥1%) were headache, pain in the extremities, pain at injection site, and increase in fibrin D dimer levels.
Thrombosis may occur if Tretten® is administered concomitantly with Factor VIIa.
There are no adequate and well-controlled studies using Tretten® in pregnant women to determine whether there is a drug-associated risk. Animal reproduction studies have not been conducted with Tretten®.
Please click here for Tretten® Prescribing Information.
Important Safety Information for Tretten®
Tretten® is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.
Tretten® may cause allergic reactions. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.
Important Safety Information for Tretten®
Tretten® is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.
Tretten® may cause allergic reactions. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.
Thromboembolic complications may occur. Monitor patients with conditions that predispose to thrombosis for signs and symptoms of thrombosis after administration of Tretten®.
Inhibitory antibodies may occur with Tretten®. Patients with inhibitory antibodies may manifest as an inadequate response to treatment. If expected plasma FXIII activity levels are not attained, or if breakthrough bleeding occurs while receiving prophylaxis, perform an assay that measures FXIII inhibitory antibody concentrations.
The most common adverse reactions reported in clinical trials (≥1%) were headache, pain in the extremities, pain at injection site, and increase in fibrin D dimer levels.
Thrombosis may occur if Tretten® is administered concomitantly with Factor VIIa.
There are no adequate and well-controlled studies using Tretten® in pregnant women to determine whether there is a drug-associated risk. Animal reproduction studies have not been conducted with Tretten®.
Please click here for Tretten® Prescribing Information.
References:
- Kohler HP, Ichinose A, Seitz R, Ariens RAS, Muszbek L; Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost. 2011;9(7):1404-1406.
- Tretten [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
- U.S. Food and Drug Administration. Licensed biological products with supporting documents. FDA Web Site. Updated August 23, 2021. Accessed February 16, 2022. https://www.fda.gov/vaccines-blood-biologics/licensed-biological-products-supporting-documents
- Hsieh L, Nugent D. Factor XIII deficiency. Hemophilia. 2008;14:1190-1200.
- Board PG, Losowky MS, Miloszewski KJA. Factor XIII: inherited and acquired deficienty. Blood Rev. 1993;7:229-242.
- National Hemophilia Foundation. MASAC recommendation regarding the use of recombinant clotting factor products with respect to pathogen transmission. http://www.hemophilia.org/sites/default/files/document/files/masac-226.pdf